Physician profile
Lorrie A Knapp
NPI 1316198609
$4,483.69
in general payments reported to CMS, 2019-2025
27 companies · $2,274 in 2025
The $2,274 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $294 · 2022: $361 · 2023: $827 · 2024: $727 · 2025: $2,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,644 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,643.57 |
| Education | $184.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $803.34 | 2021-2025 | |
| Novo Nordisk INC | $667.31 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $573.39 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $333.54 | 2021-2025 | Veozah, Myrbetriq |
| Amgen INC. | $248.01 | 2021-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $207.17 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $150.01 | 2024-2025 | Austedo Xr, Ajovy |
| Janssen Pharmaceuticals, INC | $146.08 | 2021-2023 | Xarelto |
| Neurocrine Biosciences, INC. | $139.57 | 2025 | |
| Phathom Pharmaceuticals, INC. | $136.05 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $132.18 | 2025 | Caplyta |
| Edwards Lifesciences Corporation | $122.95 | 2025 | |
| Insulet Corporation | $114.46 | 2025 | Omnipod |
| Lilly USA, LLC | $109.13 | 2021-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $108.61 | 2021-2025 | Trelegy Ellipta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $108.12 | 2024 | Watchman Flx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.92 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.73 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.29 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $29.32 | 2025 | Rexulti |
| Organogenesis INC. | $28.33 | 2024 | |
| Lundbeck LLC | $27.94 | 2025 | Rexulti |
| Abbott Laboratories | $24.12 | 2023 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $21.91 | 2024 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $19.46 | 2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $17.51 | 2021 | |
| Jazz Pharmaceuticals INC. | $16.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorrie Knapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.